The logo of Danish drugmaker Novo Nordisk in their offices in Hillerod ... Pharmaceuticalscategory US FDA expands use of ARS Pharma's allergic reaction nasal spray in 15-30 kg patients (March ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its ...

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Hikma Pharmaceuticals (HKMPF) is in talks with partners across the world to prepare to sell a generic version of Ozempic and Wegovy, as patents ...

The price negotiation process was established under former President Joe Biden's signature Inflation Reduction Act in 2022.

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.